![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
针对复发性/耐药性慢性淋巴细胞白血病的新型向疗法的网络元分析
Magdalena Monica1,2, Monika Reczek3, Paweł Kawalec2
1Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Łazarza 16, Kraków 31-530, Poland.
Therapeutic advances in medical oncology
|August 2, 2024
概括
与标准治疗相比,新型疗法显著改善了复发/耐药慢性淋巴细胞白血病 (CLL) 的无进展生存期 (PFS). 威尼托克拉克斯加上瑞图西马布 (rituximab) 显示PFS与布鲁顿氨酸激酶抑制剂 (BTKIs) 类似,而扎努布鲁丁尼布 (zanubrutinib) 的表现优于易布鲁丁尼布 (ibrutinib).
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性/耐药性慢性淋巴细胞白血病 (CLL) 存在治疗挑战.
- 最近的进展包括新型药物,如抗CD20抗体,BTK抑制剂,PI3K抑制剂和BCL-2抗剂.
- 缺乏所有治疗方案的直接比较疗效数据.
研究的目的:
- 为了比较新药,化疗和免疫治疗在复发性/耐药性CLL中的疗效和安全性.
- 用贝叶斯网络元分析 (NMA) 来进行直接和间接的治疗比较.
主要方法:
- 对复发性/耐药性CLL的随机临床试验 (RCT) 的系统性文献综述.
- 包括来自MEDLINE,Embase,Cochrane图书馆和灰色文学的研究.
- 贝叶斯网络元分析 (NMA) 来合成15个RCT的数据.
主要成果:
- 所有新药疗法显著延长了无进展生存期 (PFS),而不是标准化疗免疫疗法和免疫疗法.
- 威尼托克拉克斯 (VEN) + 利图西马布 (RTX) 证明了与基于扎努布鲁丁尼布 (ZAN),阿卡拉布鲁丁尼布 (ACA) 和易布鲁丁尼布 (IBR) 的疗法相比较的PFS.
- 赞布鲁丁尼布 (ZAN) 与ibrutinib (IBR) 单一治疗相比,显示出更优异的PFS,但与acalabrutinib (ACA) 相当.
结论:
- 与化学免疫疗法和免疫疗法相比,新型疗法在复发性/耐药性CLL中具有更高的疗效.
- 在新药中,VEN+RTX与所有布鲁顿氨酸激酶抑制剂 (BTKI) 具有相似的PFS.
- 赞努布鲁丁尼布 (ZAN) 显示出优于易布鲁丁尼布 (IBR) 的疗效,与阿卡拉布鲁丁尼布 (ACA) 的疗效相当.
更多相关视频
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
7.5K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.1K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K